SHARx: TrumpRx platform exposes issues in drug pricing and access
SHARx argues that without tackling rebate-driven economics and PBM decision-making power, efforts to lower drug prices may have limited impact on patients.
TrumpRX
Trump strikes historic deal to cut drug prices
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.